 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathophysiology of Renal Disease and Progression |
* Department of Physiology, Tulane University Health Sciences Center, New Orleans, Louisiana; and Department of Pharmacology, Kagawa University School of Medicine, Kagawa, Japan
Address correspondence to: Dr. Hiroyuki Kobori, Department of Physiology, Tulane University Health Sciences Center, 1430 Tulane Avenue, #SL39, New Orleans, LA 70112-2699. Phone: 504-988-5251; Fax: 504-988-2675; E-mail: hkobori{at}tulane.edu
Received for publication August 16, 2004. Accepted for publication April 5, 2005.
This study was performed to determine whether augmented intrarenal angiotensinogen may contribute to the enhanced renal angiotensin II (Ang II) and associated tissue injury in spontaneously hypertensive rats (SHR). SHR and Wistar-Kyoto rats (WKY) were maintained on a normal diet and killed at either 7 or 14 wk of age. Two groups of SHR received either an Ang II type 1 receptor blocker (ARB; olmesartan, 5 mg/d) or a triple therapy (hydralazine 7.5 mg/d, reserpine 0.15 mg/d, and hydrochlorothiazide 3 mg/d [HRH]) during weeks 7 through 14. Systolic BP and renal Ang II were significantly increased in SHR-14 (n = 8) compared with WKY-7, WKY-14, and SHR-7 (n = 8 each), and ARB treatment prevented these increases (n = 8). However, whereas HRH treatment prevented the development of hypertension in SHR, this combination therapy failed to decrease renal Ang II (n = 8). With the use of urine samples or fixed renal sections, renal injuries in rats were quantified in a semiautomated manner by the following six parameters: (1) urinary excretion rate of total protein, (2) glomerular sclerosis, (3) interstitial expansion, (4) and (5) numbers of monocytes/macrophages in interstitium or glomeruli, and (6) arterial proliferation. Angiotensinogen mRNA and protein levels in kidney cortex, measured by real-time reverse transcriptase—PCR and Western blot analysis, respectively, and all six parameters of renal damage were changed in parallel, and ARB treatment also prevented these increases. However, HRH treatment failed to prevent these increases. These results indicate that SHR have enhanced intrarenal angiotensinogen production that contributes to increased Ang II levels leading to the development of hypertension and renal injury in this strain.
This article has been cited by other articles:
 |
|
 |
|
  N. Ohashi, T. Yamamoto, Y. Huang, T. Misaki, H. Fukasawa, H. Suzuki, A. Togawa, S. Suzuki, Y. Fujigaki, T. Nakagawa, et al. Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1512 - F1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Satou, R. A. Gonzalez-Villalobos, K. Miyata, N. Ohashi, A. Katsurada, L. G. Navar, and H. Kobori Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells Am J Physiol Renal Physiol, July 1, 2008; 295(1): F283 - F289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobori, A. Katsurada, K. Miyata, N. Ohashi, R. Satou, T. Saito, Y. Hagiwara, K. Miyashita, and L. G. Navar Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1257 - F1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sullivan Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1220 - R1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Graciano, A. Nishiyama, K. Jackson, D. M. Seth, R. M. Ortiz, M. C. Prieto-Carrasquero, H. Kobori, and L. G. Navar Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension Am J Physiol Renal Physiol, January 1, 2008; 294(1): F161 - F169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Yang, P. K. K. Leong, and A. A. McDonough Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1197 - F1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamashita, A. Sekiguchi, T. Kato, T. Tsuneda, Y.-k. Iwasaki, K. Sagara, H. Iinuma, H. Sawada, and T. Aizawa Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 127 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Nagai, K. Izumi-Nagai, Y. Oike, T. Koto, S. Satofuka, Y. Ozawa, K. Yamashiro, M. Inoue, K. Tsubota, K. Umezawa, et al. Suppression of Diabetes-Induced Retinal Inflammation by Blocking the Angiotensin II Type 1 Receptor or Its Downstream Nuclear Factor-{kappa}B Pathway Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4342 - 4350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Katsurada, Y. Hagiwara, K. Miyashita, R. Satou, K. Miyata, N. Ohashi, L. G. Navar, and H. Kobori Novel sandwich ELISA for human angiotensinogen Am J Physiol Renal Physiol, September 1, 2007; 293(3): F956 - F960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobori, Y. Ozawa, R. Satou, A. Katsurada, K. Miyata, N. Ohashi, N. Hase, Y. Suzaki, C. D. Sigmund, and L. G. Navar Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice Am J Physiol Renal Physiol, September 1, 2007; 293(3): F938 - F945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ozawa and H. Kobori Crucial role of Rho-nuclear factor-{kappa}B axis in angiotensin II-induced renal injury Am J Physiol Renal Physiol, July 1, 2007; 293(1): F100 - F109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ozawa, H. Kobori, Y. Suzaki, and L. G. Navar Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions Am J Physiol Renal Physiol, January 1, 2007; 292(1): F330 - F339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Welsch, E. Schordan, C. Coquard, T. Massfelder, N. Fiaschi-Taesch, J.-J. Helwig, and M. Barthelmebs Abnormal Renovascular Parathyroid Hormone-1 Receptor in Hypertension: Primary Defect or Secondary to Angiotensin II Type 1 Receptor Activation? Endocrinology, September 1, 2006; 147(9): 4384 - 4391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-P. Sun, M. Kohno, P. Guo, Y. Nagai, K. Miyata, Y.-Y. Fan, S. Kimura, H. Kiyomoto, K. Ohmori, D.-T. Li, et al. Involvements of Rho-Kinase and TGF-beta Pathways in Aldosterone-Induced Renal Injury J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2193 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kondo, H. Kiyomoto, T. Yamamoto, A. Miyatake, G.-P. Sun, M. Rahman, H. Hitomi, K. Moriwaki, T. Hara, S. Kimura, et al. Effects of Calcium Channel Blockade on Angiotensin II-Induced Peritubular Ischemia in Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1047 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Alexander Fetal programming of hypertension Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R1 - R10. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
